| Date Filed | Type | Description |
| 04/28/2021 |
GN
| US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche's Tecentriq for previously untreated metastatic bladder cancer |
| 04/28/2021 |
GN
| Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people |
| 04/27/2021 |
GN
| US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche's Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer |
| 04/23/2021 |
GN
| CHMP recommends EU approval of Roche's ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD) |
| 04/23/2021 |
GN
| Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy |
| 04/22/2021 |
GN
| Roche purchases shares in tender offer for GenMark Diagnostics, Inc. |
| 04/21/2021 |
GN
| Roche reports solid results in the first quarter of 2021 |
| 04/21/2021 |
GN
| Roche fait état de solides résultats au premier trimestre 2021 |
| 04/21/2021 |
GN
| Roche mit soliden Ergebnissen im ersten Quartal 2021 |
| 04/08/2021 |
GN
| New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio |
| 04/07/2021 |
GN
| Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types |
| 03/31/2021 |
GN
| Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging |
| 03/26/2021 |
GN
| Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer |
| 03/25/2021 |
GN
| Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash |
| 03/23/2021 |
GN
| Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency |
| 03/23/2021 |
GN
| New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 |
| 03/22/2021 |
GN
| Roche provides update on tominersen programme in manifest Huntington's disease |
| 03/22/2021 |
GN
| Pivotal Phase III study shows Roche's Tecentriq helped people with early lung cancer live longer without their disease returning |
| 03/17/2021 |
GN
| Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs |
| 03/16/2021 |
GN
| Roche Annual General Meeting 2021 |
| 03/16/2021 |
GN
| Assemblée générale Roche 2021 |
| 03/16/2021 |
GN
| Roche Generalversammlung 2021 |
| 03/16/2021 |
GN
| Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations |
| 03/16/2021 |
GN
| New two-year data show Roche's Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) |
| 03/15/2021 |
GN
| Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample |
| 03/11/2021 |
GN
| Roche's awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems |
| 03/11/2021 |
GN
| Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia |
| 03/08/2021 |
GN
| Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer |
| 03/05/2021 |
GN
| Roche's Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition |
| 02/26/2021 |
GN
| Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany |
| 02/26/2021 |
GN
| EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 |
| 02/26/2021 |
GN
| Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older |
| 02/25/2021 |
GN
| Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine |
| 02/12/2021 |
GN
| New phase III data show Roche's faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients |
|